Currently out of the existing stock ratings of Robyn Karnauskas, 266 are a BUY (85.26%), 44 are a HOLD (14.1%), 2 are a SELL (0.64%).

Robyn Karnauskas

Work Performance Price Targets & Ratings Chart

Analyst Robyn Karnauskas works at TRUIST with a stock forecast success ratio of 50.61% fulfilled within 274.73 days on average.

Robyn Karnauskas’s has documented 629 price targets and ratings displayed on 33 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on MRK, Merck mpany at 28-Mar-2024.

Wall Street Analyst Robyn Karnauskas

Analyst best performing recommendations are on DRNA (DICERNA PHARMACEUTICALS).
The best stock recommendation documented was for DRNA (DICERNA PHARMACEUTICALS) at 11/18/2019. The price target of $24 was fulfilled within 1 day with a profit of $2.61 (12.2%) receiving and performance score of 122.02.

Average potential price target upside

of $105.81 (21.85%) on REGN (REGENERON PHARMACEUTICALS).
of $69.47 (26.32%) on BIIB (BIOGEN).
of $56.61 (12.58%) on LLY (ELI LILLY AND COMPANY).

ABBV AbbVie ALXN Alexion Pharmaceuticals AMGN Amgen BIIB Biogen BMRN Biomarin Pharmaceutical BTAI BioXcel Therapeutics DCPH Deciphera Pharmaceuticals LLC GILD Gilead Sciences IMVT Immunovant KOD Kodiak Sciences PTCT PTC Therapeutics RCUS Arcus Biosciences REGN Regeneron Pharmaceuticals VRTX Vertex Pharmaceuticals APLT Applied Therapeutics BMY Bristol-Myers Squibb Company DRNA Dicerna Pharmaceuticals FATE Fate Therapeutics INFI Infinity Pharmaceuticals MRK Merck mpany PFE Pfizer ASMB Assembly Biosciences NCNA NuCana PLC SRPT Sarepta Therapeutics CELG Celgene OPT Opthea Ltd ROIV Roivant Sciences Ltd TIL Instil Bio . MEIP MEI Pharma MNTA Momenta Pharmaceuticals LLY Eli Lilly and Company QURE Uniqure NV CHRS Coherus BioSciences

Show more stocks

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Carter Gould (BARCLAYS)